Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Klinik for Fodterapi - Hjerting ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Bankruptcy risk for industry   0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8% 0.8%   Bankruptcy risk   2.7% 1.5% 1.4% 1.3% 1.5% 0.9% 11.3% 11.3%   Credit score (0-100)   61 75 76 79 76 89 22 22   Credit rating   BBB A A A A A BB BB   Credit limit (kDKK)   0.0 1.7 5.4 19.0 6.3 110.7 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   830 952 1,262 1,458 1,230 1,486 0.0 0.0   EBITDA   392 340 472 711 206 401 0.0 0.0   EBIT   367 294 397 644 114 329 0.0 0.0   Pre-tax profit (PTP)   368.9 296.4 400.9 649.9 122.4 336.2 0.0 0.0   Net earnings   287.3 231.0 312.3 507.8 96.2 262.2 0.0 0.0   Pre-tax profit without non-rec. items   369 296 401 650 122 336 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Tangible assets total   79.4 56.7 32.5 142 134 213 0.0 0.0   Shareholders equity total   342 288 370 878 974 1,086 886 886   Interest-bearing liabilities   0.0 7.2 145 12.5 4.5 8.0 0.0 0.0   Balance sheet total (assets)   527 619 803 1,259 1,331 1,342 886 886   Net Debt   -54.9 -10.3 79.8 -140 -11.5 -49.4 -886 -886     See the entire balance sheet 1000.0 Volume  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   830 952 1,262 1,458 1,230 1,486 0.0 0.0   Gross profit growth   38.3% 14.8% 32.6% 15.5% -15.6% 20.8% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   527 619 803 1,259 1,331 1,342 886 886   Balance sheet change%   11.0% 17.5% 29.7% 56.8% 5.8% 0.8% -33.9% 0.0%   Added value   392.2 340.5 471.6 710.9 180.1 400.7 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -17 -69 -98 43 -101 8 -213 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   44.2% 30.9% 31.5% 44.2% 9.2% 22.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   73.8% 51.9% 56.6% 63.2% 9.5% 25.2% 0.0% 0.0%   ROI %   129.9% 90.5% 97.4% 91.6% 13.0% 32.1% 0.0% 0.0%   ROE %   104.2% 73.4% 94.9% 81.4% 10.4% 25.4% 0.0% 0.0%   1000.0 Solidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Equity ratio %   64.9% 46.5% 46.1% 69.7% 73.2% 81.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -14.0% -3.0% 16.9% -19.7% -5.6% -12.3% 0.0% 0.0%   Gearing %   0.0% 2.5% 39.2% 1.4% 0.5% 0.7% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 32.2% 2.2% 1.5% 0.6% 3.2% 0.0% 0.0%   1000.0 Liquidity  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Quick Ratio   4.0 0.3 0.4 1.5 1.3 2.2 0.0 0.0   Current Ratio   4.2 0.3 0.4 1.6 1.4 2.3 0.0 0.0   Cash and cash equivalent   54.9 17.4 65.1 152.3 16.0 57.3 0.0 0.0   1000.0 Capital use efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   307.5 -174.4 -184.5 133.1 116.6 226.6 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/9 2020 2020/9 2021 2021/9 2022 2022/9 2023 2023/9 2024 2024/9 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   392 340 472 711 180 401 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   392 340 472 711 206 401 0 0   EBIT / employee   367 294 397 644 114 329 0 0   Net earnings / employee   287 231 312 508 96 262 0 0